Home>Genentech Support Programs Genentech support programs Genentech provides support to healthcare organizations that use our products to treat patients. The comprehensive Genentech® Product Replacement Program allows physicians, under specific circumstances, to return certain Genentech products for replacement. And for 20 years, Genentech has been committed to making sure price is not a barrier to access for patients. If you have patients who are uninsured or deemed uninsured due to payer denial, they may qualify for the Genentech® Access to Care Foundation.

Indication: Activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS in the full prescribing information).

Safety Information: All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in appropriate patients. Not all patients with acute ischemic stroke will be eligible for Activase therapy, including patients with evidence of recent or active bleeding; recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke; uncontrolled high blood pressure; or impaired blood clotting.